 |
| Proton Pump Inhibitors Market |
The global proton pump inhibitors market is estimated to be valued at US$2.9 billion in 2023 and is expected
to exhibit a CAGR of 4.30% over the
forecast period 2023-2030, as
highlighted in a new report published by Coherent Market Insights.
Market Overview:
Proton pump inhibitors (PPIs) are a group of medications that reduce the
production of acid in the stomach, providing relief from conditions such as
gastroesophageal reflux disease (GERD) and peptic ulcers. PPIs are widely
prescribed due to their efficacy in managing acid-related disorders. They offer
advantages such as long-lasting relief, potent acid suppression, and improved
patient outcomes. The growing need to manage GERD and other acid-related
disorders is driving the demand for proton pump inhibitors globally.
Market Key Trends:
One key trend in the Global
Proton Pump Inhibitors Market is the increasing adoption of
over-the-counter (OTC) PPIs. OTC PPIs allow patients to self-medicate and
access the medication without a prescription. This trend is driven by the
convenience and cost-effectiveness of OTC products, as consumers can save on
healthcare costs and avoid visits to healthcare providers. Additionally, the
availability of a range of OTC PPIs in retail outlets and online pharmacies
further promotes their usage. The rise in OTC PPIs is expected to offer new
growth opportunities for market players and further expand the consumer base
for these medications.
Porter's Analysis:
The proton pump inhibitors market is expected to experience moderate threats from
new entrants. While there may be potential for new players to enter the market,
the high barriers to entry, such as stringent regulatory requirements and
strong brand loyalty, can deter new entrants. Existing key players in the
market have already established their strong foothold and have significant
market share, which can make it challenging for new entrants to compete
effectively.
The bargaining power of buyers in the proton pump inhibitors market is expected
to be moderate. Buyers, such as hospitals, pharmacies, and healthcare
providers, have some negotiating power due to the availability of multiple
options and generic alternatives. However, the crucial nature of proton pump
inhibitors to manage acid-related disorders gives the key players an advantage
in maintaining control over pricing and product availability.
The bargaining power of suppliers in the proton pump inhibitors market is
expected to be moderate. Key players in the market have established
relationships with suppliers, ensuring a steady supply of raw materials and
resources. However, in the event of any disruption or shortage, suppliers may
have some leverage to negotiate better terms or increase prices.
The threat of new substitutes in the proton pump inhibitors market is expected
to be low. Proton pump inhibitors are widely recognized and prescribed by
healthcare professionals for the treatment of gastric acid disorders, and there
are limited alternatives available that can provide similar efficacy. This lack
of viable substitutes reduces the threat of substitution in the market.
Competitive rivalry in the proton pump inhibitors market is expected to be
high. Key players, including AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., and
Cadila Pharmaceuticals Limited, among others, compete fiercely to capture and
maintain market share. This competition is driven by product innovation,
marketing strategies, and pricing tactics to gain a competitive edge.
Key Takeaways:
The global proton pump inhibitors market is expected to witness significant
growth, exhibiting a CAGR of 4.30% over
the forecast period from 2023 to 2027. This growth can be attributed to the
increasing prevalence of gastroesophageal reflux disease (GERD) and peptic
ulcers, coupled with the rising geriatric population. Proton pump inhibitors
are highly effective in managing these acid-related disorders, driving their
demand.
In terms of regional analysis, North America is anticipated to be the
fastest-growing and dominating region in the proton pump inhibitors market.
This can be attributed to the high prevalence of GERD and the presence of key
market players in the region. Additionally, favorable government initiatives,
reimbursement policies, and advanced healthcare infrastructure contribute to
the market's growth in North America.
Key players operating in the proton pump inhibitors market include AstraZeneca
PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, and Eisai
Pharmaceuticals India Pvt. Ltd, among others. These key players contribute
significantly to the market's growth through product development, strategic
collaborations, and mergers and acquisitions. Their strong market presence and
extensive distribution networks enable them to maintain their competitive
position in the market.
In conclusion, the proton pump inhibitors market is expected to witness
substantial growth due to increasing prevalence of acid-related disorders and a
growing geriatric population. The market is characterized by moderate threats
from new entrants, moderate bargaining power of buyers and suppliers, low
threat of substitutes, and high competitive rivalry among key players. North
America is projected to be the fastest-growing region, while AstraZeneca
PLC/AB, Bayer AG, Pfizer Inc., and Cadila Pharmaceuticals Limited are some of
the key players in the market.